Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128718) titled 'A Prospective, Single-Arm, Phase II Clinical Study of Nimotuzumab Combined with Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Resectable Oral Squamous Cell Carcinoma' on July 24.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital, Zhejiang University School of Medicine
Condition:
Oral Squamous Cell Carcinoma
Intervention:
Treatment group:Nimotuzumab injection 400mg, day 1, weekly for 6 cycles
Albumin-bound paclitaxel 260mg/m^2, day 1, every 3 weeks for 2 cycles
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 202...